

2031 patients not treated with rituximab,			
Score	Risk group	5-yr OS, percent	CR rate, percent
0 to 1	Low risk	73	87
2	Low-intermediate risk	51	67
3	High-intermediate risk	43	55
4 to 5	High risk	26	44
Validation cohort: 1063 treated with rituximab			
Score	3-yr EFS	3-yr PFS	3-yr OS
0 to 1	81	87	91
2	69	75	81
3	53	59	65
4 to 5	50	50	59
Age adjusted International Prognostic Index[1]			
761 patients >60 years of age			
Score	Risk Group	5-yr OS, percent	CR rate, percent
0	Low risk	56	91
1	Low-intermediate risk	44	71
2	High-intermediate risk	37	56
3	High risk	21	36

EFS: event-free survival; PFS: progression-free survival.

1. Adapted from: *The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med* 1993; 329:987.

2. Adapted from: *Ziepert, M, Hasenclever, D, Kuhnt, E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol* 2010; 28:2373.